{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:21:04Z","timestamp":1792092064503,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymgme.2025.109705","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:14:54Z","timestamp":1765901694000},"page":"109705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dietetic guidance for nutritional management of people with phenylketonuria receiving sepiapterin"],"prefix":"10.1016","volume":"147","author":[{"given":"Anita","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Ahring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Bledsoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Giorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kogelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kopesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek M.J.","family":"van Wegberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109705_bb0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2025.109705_bb0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109705_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109125","article-title":"European guidelines on diagnosis and treatment of phenylketonuria: first revision","volume":"145","author":"van Wegberg","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","article-title":"PKU dietary handbook to accompany PKU guidelines","volume":"15","author":"MacDonald","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109705_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101289","article-title":"Phenylalanine hydroxylase deficiency diagnosis and management: a 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Smith","year":"2025","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109705_bb0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13023-020-01541-2","article-title":"Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe","volume":"15","author":"Lowe","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109705_bb0035","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/nu15183940","article-title":"Expert consensus on the long-term effectiveness of medical nutrition therapy and its impact on the outcomes of adults with phenylketonuria","volume":"15","author":"Rocha","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109705_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1177392819857089","article-title":"A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria","volume":"13","author":"Hydery","year":"2019","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.ymgme.2025.109705_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ymgme.2025.109705_bb0055","first-page":"1","article-title":"CADTH Reimbursement Recommendation Pegvaliase (Palynziq)","volume":"2","author":"Canadian Journal of Health Technologies","year":"2022","journal-title":"Canadian Journal of Health Technologies"},{"key":"10.1016\/j.ymgme.2025.109705_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107625","article-title":"Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients - a nationwide study of health insurance claims data","volume":"139","author":"Charri\u00e8re","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0065","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/nu16132064","article-title":"Blood phenylalanine levels in patients with phenylketonuria from Europe between 2012 and 2018: is it a changing landscape?","volume":"16","author":"Pinto","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0070","author":"BioMarin Pharmaceutical Inc."},{"key":"10.1016\/j.ymgme.2025.109705_bb0075","author":"BioMarin International Limited"},{"key":"10.1016\/j.ymgme.2025.109705_bb0080","author":"Biomarin Pharmaceuticals, Inc"},{"key":"10.1016\/j.ymgme.2025.109705_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","article-title":"The genetic landscape and epidemiology of phenylketonuria","volume":"107","author":"Hillert","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109705_bb0090","first-page":"101084","article-title":"Pegvaliase for the treatment of phenylketonuria: final results of a long-term phase 3 clinical trial program","volume":"39","author":"Harding","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109705_bb0095","author":"BioMarin Pharmaceutical Inc"},{"key":"10.1016\/j.ymgme.2025.109705_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107697","article-title":"Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria","volume":"140","author":"Ishige","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0105","author":"BioMarin International Limited"},{"key":"10.1016\/j.ymgme.2025.109705_bb0110","author":"Biomarin Pharmaceuticals Inc"},{"key":"10.1016\/j.ymgme.2025.109705_bb0115","author":"BioMarin Pharmaceutical Inc"},{"key":"10.1016\/j.ymgme.2025.109705_bb0120","author":"PTC Therapeutics International Limited"},{"key":"10.1016\/j.ymgme.2025.109705_bb0125","author":"PTC Therapeutics Australia Pty Limited"},{"key":"10.1016\/j.ymgme.2025.109705_bb0130","author":"PTC Therapeutics, Inc"},{"key":"10.1016\/j.ymgme.2025.109705_bb0135","author":"swissmedic"},{"key":"10.1016\/j.ymgme.2025.109705_bb0140","unstructured":"PTC Therapeutics, Product Monograph, Sephience, Health Canada Available online: 2025. https:\/\/pdf.hres.ca\/dpd_pm\/00081969.PDF Accessed on 4 November 2025."},{"key":"10.1016\/j.ymgme.2025.109705_bb0145","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3390\/ph17111411","article-title":"A phase 1 study to assess the pharmacokinetics, food effect, safety, and tolerability of sepiapterin in healthy Japanese and non-Japanese participants","volume":"17","author":"Gao","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ymgme.2025.109705_bb0150","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(24)01556-3","article-title":"Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial","volume":"404","author":"Muntau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2025.109705_bb0155","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ymgme.2019.02.001","article-title":"Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers","volume":"126","author":"Smith","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ymgme.2025.109705_bb0165","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cpdd.1363","article-title":"Relative oral bioavailability and food effects of two sepiapterin formulations in healthy participants","volume":"13","author":"Gao","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymgme.2025.109705_bb0170","author":"Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2025.109705_bb0175","doi-asserted-by":"crossref","first-page":"102891","DOI":"10.1016\/j.gimo.2025.102891","article-title":"Interim results from the APHENITY extension study: sepiapterin reduces blood Phe with improved dietary Phe tolerance in participants with phenylketonuria","volume":"3","author":"Longo","year":"2025","journal-title":"Genet. Med. Open."},{"key":"10.1016\/j.ymgme.2025.109705_bb0180","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.3390\/nu15163506","article-title":"Phenylalanine tolerance over time in phenylketonuria: a systematic review and meta-analysis","volume":"15","author":"Pinto","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0185","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.3390\/nu14204268","article-title":"Impact of fruit and vegetable protein vs. milk protein on metabolic control of children with phenylketonuria: a randomized crossover controlled trial","volume":"14","author":"Pinto","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2019.04.004","article-title":"International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria","volume":"127","author":"Muntau","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2019.12.011","article-title":"Does the 48-hour BH4 loading test miss responsive PKU patients?","volume":"129","author":"van Wegberg","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2021.01.013","article-title":"Defining tetrahydrobiopterin responsiveness in phenylketonuria: survey results from 38 countries","volume":"132","author":"Evers","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ymgme.2013.09.001","article-title":"Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes","volume":"110","author":"Cleary","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13023-025-03890-2","article-title":"The influence of menstrual cycle on metabolic control and diet in patients with phenylketonuria","volume":"20","author":"Horka","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109705_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.03.002","article-title":"Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study","volume":"121","author":"Bilder","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0220","doi-asserted-by":"crossref","first-page":"108","DOI":"10.14740\/jem581","article-title":"Food neophobia in patients with phenylketonuria","volume":"9","author":"Tonon","year":"2019","journal-title":"J. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2025.109705_bb0225","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/nu14132565","article-title":"Early introduction of allergenic foods and the prevention of food allergy","volume":"14","author":"Trogen","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/nu13031040","article-title":"Protein substitute requirements of patients with phenylketonuria on BH4 treatment: a systematic review and meta-analysis","volume":"13","author":"Ilgaz","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109705_bb0235","first-page":"62","article-title":"The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: effects on metabolic control, nutritional habits and nutrient supply","volume":"4","author":"Thiele","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109705_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109187","article-title":"The clinical utility of short-term protein substitute use during intercurrent illness in BH4-responsive phenylketonuria","volume":"145","author":"Akbulut","year":"2025","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225006973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225006973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:19:40Z","timestamp":1768551580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225006973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1096719225006973"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109705","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dietetic guidance for nutritional management of people with phenylketonuria receiving sepiapterin","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109705"}}